Flutemetamol F 18 (Flutemetamol F 18)
Overview of Flutemetamol F 18
Flutemetamol is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate ß amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimers disease (AD) or other causes of cognitive decline. A negative Flutemetamol scan indicates sparse to no neuritic plaques, and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Vizamyl scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions, as well as older people with normal cognition. Flutemetamol is an adjunct to other diagnostic evaluations. Chemically, flutemetamol F 18, is described as 2-[3-[18F]fluoro-4-(methylamino) phenyl]-6-benzothiazolol
Indication of Flutemetamol F 18
Flutemetamol F 18 is primarily indicated in conditions like Alzheimer's disease.
Contraindication of Flutemetamol F 18
No data regarding the contra indications of Flutemetamol F 18 is available.
Side Effects of Flutemetamol F 18
No data regarding the side effects produced by Flutemetamol F 18 is available
Precautions of Flutemetamol F 18
Hypersensitivity reactions. Image interpretation errors (especially false positives) have been observed. Radiation risk: Flutemetamol, similar to all radiopharmaceuticals, contributes to a patient�s long-term cumulative radiation exposure. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure .